<DOC>
	<DOCNO>NCT00005826</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase II trial study effectiveness nitrocamptothecin treat patient glioblastoma multiforme .</brief_summary>
	<brief_title>Nitrocamptothecin Treating Patients With Glioblastoma Multiforme</brief_title>
	<detailed_description>OBJECTIVES : I. Assess therapeutic activity toxicity nitrocamptothecin patient glioblastoma multiforme . II . Determine overall response , duration response , progression free survival patient treatment . OUTLINE : This multicenter study . Patients receive nitrocamptothecin orally daily day 1-5 . Treatment continue every 7 day absence disease progression unacceptable toxicity . Patients follow every 6 week disease progression absence treatment . PROJECTED ACCRUAL : A total 14-25 patient accrue study .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Rubitecan</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm glioblastoma multiforme Recurrent disease confirm CT MRI Bidimensionally measurable disease At least one lesion large diameter least 2 cm PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : At least 3 month Hematopoietic : Absolute neutrophil count least 2,000/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin le 1.5 time upper limit normal ( ULN ) Alkaline phosphatase transaminases great 2.5 time ULN ( great 5 time ULN case liver metastasis ) Renal : Creatinine great 1.7 mg/dL Cardiovascular : No history ischemic heart disease past 6 month Other : Not pregnant nursing Fertile patient must use effective contraception No prior concurrent malignancy except cone biopsied carcinoma cervix adequately treat basal squamous cell skin carcinoma No unstable systemic disease No active uncontrolled infection No psychological , familial , sociological , geographical condition would preclude study PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : At least 6 week since prior adjuvant chemotherapy No prior concurrent chemotherapy allow Endocrine therapy : Concurrent corticosteroid allow Stable decrease dose least 2 week Radiotherapy : No high dose radiotherapy , stereotactic radiosurgery , internal radiotherapy unless recurrence histologically confirm At least 3 month since prior radiotherapy brain Surgery : No prior surgery recurrent brain tumor except biopsy At least 3 month since prior surgery primary brain tumor Other : No concurrent anticancer therapy No concurrent investigational therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>adult glioblastoma</keyword>
	<keyword>adult giant cell glioblastoma</keyword>
	<keyword>adult gliosarcoma</keyword>
</DOC>